Based on the above characteristics, 68Ga-labeled PSMA has been successfully developed as a nuclear medicine clinically, and has been reported in the diagnosis of liver cancer and kidney cancer in addition to prostate cancer (6, 7). Here, FOLH1 is linked to prostate carcinoma.